What is ESCALON MEDICAL CORP's earnings per share (EPS)?

ESCALON MEDICAL CORP (ESMC) reported diluted earnings per share of $0.00 for fiscal year 2025. This represents a 100.0% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

ESCALON MEDICAL CORP (ESMC) Financials

ESMC

Trailing 12 months to March 31, 2026

Revenue $11.4M -11.6% YoY

Net Income $1.9M +198.8% YoY

EPS (Diluted) $0.11 +120.0% YoY

Free Cash Flow -$144K -1008.5% YoY

Market Cap $1.2M as of Sep 14, 2026

Price / Sales 0.1x on $11.4M revenue, trailing 12 months to March 31, 2026

Price / Earnings 0.6x on $1.9M net income, trailing 12 months to March 31, 2026

Price / Book 0.3x on $4.1M equity, Q3 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Sep 14, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q3 FY2026, ended Mar 31, 2026 Reported May 15, 2026 Currency USD FYE June

Newest figures come from the 10-Q for Q3 FY2026, filed May 15, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the ESMC SEC filings page.

ESCALON MEDICAL CORP (ESMC) reported $11.4M in revenue over the twelve months to Mar 31, 2026, down 11.6% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI ESMC FY2025 2026-08-29

Escalon’s modest revenue base is converting unevenly: gross-margin recovery is restoring profit, while working capital drives cash swings.

The FY2024-to-FY2025 rebound was not sales-led: revenue was nearly flat, while gross margin improved from 42.9% to 45.8% and operating margin moved from -0.9% to 1.1%. That pattern points to cost-of-revenue improvement and operating-cost absorption rather than broad volume acceleration, leaving only a 0.9% net margin. Cash conversion also recovered, with operating cash flow of $381K nearly matching free cash flow of $377K, indicating that limited reinvestment did not materially dilute internally generated cash.

The balance sheet became less burdened over the recent period: debt-to-equity declined from 1.7x in FY2023 to 1.6x in FY2025, while the current ratio improved from 1.6x to 1.7x. Together, those movements suggest improved short-term coverage alongside modest deleveraging, not merely a one-year earnings fluctuation.

Working capital changed composition as cash generation returned: inventory increased from $1.6M to $2.1M, while receivables fell from $2.1M to $1.5M. The combination suggests customer collections helped offset inventory investment, making operating cash flow more informative than net income alone.

Financial Health Signals

Financial health score not available

ESCALON MEDICAL CORP does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Altman Z-Score Distress

-16.00

ESCALON MEDICAL CORP scores -16.00, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($1.2M) relative to total liabilities ($3.1M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

7/8

ESCALON MEDICAL CORP passes 7 of 8 computable financial strength tests (1 of the nine could not be computed from available data). All 4 profitability signals pass (positive income, cash flow, and earnings quality), all 2 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.

Earnings Quality Cash-Backed

3.61x

For every $1 of reported earnings, ESCALON MEDICAL CORP generates $3.61 in operating cash flow ($381K OCF vs $106K net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.

Interest Coverage Safe

5.87x

ESCALON MEDICAL CORP earns $5.87 in operating income for every $1 of interest expense ($133K vs $23K). This wide margin provides strong safety for debt servicing, even if earnings decline temporarily.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$2.6M

YoY-24.9%

QoQ-27.4%

5Y CAGR+2.3%

10Y CAGR-1.7%

ESCALON MEDICAL CORP generated $2.6M in revenue in Q3 2026. This represents a decrease of 24.9% from the same quarter a year earlier. Against the prior quarter it is down 27.4%.

EBITDA

-$416K

YoY-246.1%

QoQ-488.5%

ESCALON MEDICAL CORP's EBITDA was -$416K in Q3 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 246.1% from the same quarter a year earlier. Against the prior quarter it is down 488.5%.

Net Income

$2.4M

YoY+774.3%

QoQ+2329.9%

ESCALON MEDICAL CORP reported $2.4M in net income in Q3 2026. This represents an increase of 774.3% from the same quarter a year earlier. Against the prior quarter it is up 2329.9%.

EPS (Diluted)

$0.16

YoY+700.0%

ESCALON MEDICAL CORP earned $0.16 per diluted share (EPS) in Q3 2026. This represents an increase of 700.0% from the same quarter a year earlier.

Cash & Balance Sheet

Free Cash Flow

$281K

YoY+815.4%

QoQ+154.3%

ESCALON MEDICAL CORP generated $281K in free cash flow in Q3 2026, representing cash available after capex. This represents an increase of 815.4% from the same quarter a year earlier. Against the prior quarter it is up 154.3%.

Cash & Debt

$3.3M

YoY+517.9%

QoQ+890.6%

5Y CAGR+15.1%

10Y CAGR+18.4%

ESCALON MEDICAL CORP held $3.3M in cash as of Q3 2026; long-term debt is not reported for that period.

Shares Outstanding

YoY0.0%

5Y CAGR0.0%

10Y CAGR-0.1%

ESCALON MEDICAL CORP had 7M shares outstanding in Q3 2026. That is unchanged from the same quarter a year earlier.

Dividends Per Share

Not reported for Q3 2026.

Margins & Returns

Gross Margin

36.3%

YoY-9.8pp

QoQ-7.0pp

5Y change-4.2pp

10Y change-12.7pp

ESCALON MEDICAL CORP's gross margin was 36.3% in Q3 2026, indicating the percentage of revenue retained after direct costs. This is down 9.8 percentage points from the same quarter a year earlier. Against the prior quarter it is down 7.0 percentage points.

Operating Margin

-16.1%

YoY-24.0pp

QoQ-18.8pp

5Y change-10.4pp

10Y change-13.5pp

ESCALON MEDICAL CORP's operating margin was -16.1% in Q3 2026, reflecting core business profitability. This is down 24.0 percentage points from the same quarter a year earlier. Against the prior quarter it is down 18.8 percentage points.

Net Margin

91.0%

YoY+83.2pp

QoQ+88.3pp

5Y change+96.9pp

10Y change+93.6pp

ESCALON MEDICAL CORP's net profit margin was 91.0% in Q3 2026, showing the share of revenue converted to profit. This is up 83.2 percentage points from the same quarter a year earlier. Against the prior quarter it is up 88.3 percentage points.

Return on Equity

57.2%

YoY+45.4pp

QoQ+51.7pp

5Y change+68.0pp

10Y change+60.7pp

ESCALON MEDICAL CORP's ROE was 57.2% in Q3 2026, measuring profit generated per dollar of shareholder equity. This is up 45.4 percentage points from the same quarter a year earlier. Against the prior quarter it is up 51.7 percentage points.

Capital Allocation

R&D Spending

$30K

YoY-81.8%

QoQ-77.2%

5Y CAGR-32.6%

10Y CAGR-22.2%

ESCALON MEDICAL CORP invested $30K in research and development in Q3 2026. This represents a decrease of 81.8% from the same quarter a year earlier. Against the prior quarter it is down 77.2%.

Capital Expenditures

ESCALON MEDICAL CORP reported no capital expenditure in Q3 2026.

Share Buybacks

Not reported for Q3 2026.

ESMC Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

ESMC quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Revenue	$11.4M	$12.0M+0.5%	$12.0M-1.6%	$12.2M+13.8%	$10.7M+2.2%	$10.5M+11.4%	$9.4M-2.4%	$9.6M-15.6%	$11.4M+1.5%	$11.2M-3.0%	$11.6M-11.9%	$13.1M+142.3%	$5.4M-52.9%	$11.5M+0.3%	$11.5M-55.2%	$25.6M
Cost of Revenue	$6.7M	$6.5M-4.4%	$6.8M+2.0%	$6.7M+9.9%	$6.1M+0.9%	$6.0M+16.3%	$5.2M+4.0%	$5.0M-20.7%	$6.3M+3.6%	$6.1M-1.9%	$6.2M-11.5%	$7.0M+11.4%	$6.3M+6.5%	$5.9M+2.5%	$5.8M-66.6%	$17.3M
Gross Profit	$4.7M	$5.5M+7.1%	$5.1M-6.1%	$5.5M+19.0%	$4.6M+4.1%	$4.4M+5.4%	$4.2M-9.2%	$4.6M-9.3%	$5.1M-1.0%	$5.2M-4.2%	$5.4M-12.2%	$6.1M+803.6%	-$871K-115.6%	$5.6M-1.9%	$5.7M-31.5%	$8.3M
R&D Expenses	$669K	$753K+9.4%	$688K-15.9%	$819K-17.4%	$991K+11.3%	$890K-20.7%	$1.1M+51.7%	$740K+47.9%	$500K-52.5%	$1.1M-27.4%	$1.5M+11.4%	$1.3M-0.4%	$1.3M+18.2%	$1.1M+10.0%	$1.0M-37.3%	$1.6M
SG&A Expenses	$5.0M	$4.6M+1.4%	$4.6M+9.0%	$4.2M+2.4%	$4.1M+14.4%	$3.6M-7.8%	$3.9M-6.5%	$4.1M-5.8%	$4.4M-4.5%	$4.6M-9.2%	$5.1M-13.8%	$5.9M+15.0%	$5.1M-10.6%	$5.7M-4.9%	$6.0M-43.7%	$10.7M
Operating Income	-$895K	$133K+227.5%	-$104K-121.8%	$479K+201.8%	-$470K-1295.0%	-$34K+97.6%	-$1.4M-453.3%	-$253K-223.6%	$205K+132.7%	-$627K+45.0%	-$1.1M-8.4%	-$1.1M-194.3%	-$358K+71.0%	-$1.2M+6.6%	-$1.3M+72.9%	-$4.9M
EBITDA	N/A	$171K+392.6%	-$58K-111.2%	$524K+224.2%	-$422K-3893.4%	$11K+100.8%	-$1.3M-565.4%	-$203K-179.9%	$254K+143.7%	-$581K+47.9%	-$1.1M-7.5%	-$1.0M-200.9%	-$345K+71.7%	-$1.2M+6.0%	-$1.3M+69.8%	-$4.3M
Interest Expense	$16K	$23K+9.2%	$21K-4.3%	$22K+18.0%	$18K-15.7%	$22K+60.8%	$14K-21.7%	$17K-86.2%	$126K+25.3%	$100K+780.1%	$11K	$0	$0-100.0%	$79K-76.6%	$339K+4.9%	$324K
Income Tax	$0	$0	$0	$0	$0	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$0	$0	$0+100.0%	-$240K
Net Income	$1.9M	$106K+184.2%	-$125K-127.4%	$457K+2426.6%	$18K+134.8%	-$52K+92.0%	-$650K-160.1%	-$250K-142.8%	$584K+180.3%	-$727K+36.9%	-$1.2M-112.8%	-$541K-41.7%	-$382K-114.6%	$2.6M+144.1%	-$5.9M-3.3%	-$5.8M
EPS (Basic)	N/A	$0.00+100.0%	-$0.02-166.7%	$0.03	$0.00+100.0%	-$0.01+88.9%	-$0.09-125.0%	-$0.04-157.1%	$0.07+170.0%	-$0.10+33.3%	-$0.15-114.3%	-$0.07-40.0%	-$0.05-114.3%	$0.35+144.3%	-$0.79-2.6%	-$0.77
EPS (Diluted)	$0.11	$0.00+100.0%	-$0.02	$0.03	$0.00+100.0%	-$0.01+88.9%	-$0.09-125.0%	-$0.04	$0.06+160.0%	-$0.10+33.3%	-$0.15-114.3%	-$0.07-40.0%	-$0.05-114.3%	$0.35+144.3%	-$0.79-2.6%	-$0.77
Diluted Shares (Avg)	N/A	14M+92.2%	7M	14M+2.6%	13M+78.3%	7M0.0%	7M0.0%	7M	9M+21.1%	8M+0.1%	8M+0.2%	8M0.0%	8M0.0%	8M0.0%	8M0.0%	8M

Metric	Q3'2610-Q	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K
Revenue	$2.6M-24.9%	$3.6M+11.5%	$2.7M-3.8%	$2.6M-26.0%	$3.5M+28.9%	$3.2M+12.2%	$2.8M-5.6%	$3.5M+10.7%
Cost of Revenue	$1.7M-11.3%	$2.0M+23.6%	$1.6M-0.9%	$1.4M-27.7%	$1.9M+18.7%	$1.6M+2.4%	$1.6M-4.9%	$2.0M+19.2%
Gross Profit	$947K-40.8%	$1.6M-1.1%	$1.1M-7.6%	$1.1M-23.6%	$1.6M+43.3%	$1.6M+24.8%	$1.2M-6.4%	$1.5M+0.9%
R&D Expenses	$30K-81.8%	$131K-15.9%	$216K+53.4%	$292K+68.6%	$165K+5.7%	$156K+5.6%	$141K-33.4%	$173K-2.5%
SG&A Expenses	$1.3M+15.3%	$1.3M+14.1%	$1.1M+0.7%	$1.2M+3.8%	$1.2M+3.7%	$1.2M-1.9%	$1.1M-0.1%	$1.2M+7.9%
Operating Income	-$419K-251.9%	$99K-61.4%	-$203K-652.2%	-$372K-368.8%	$276K+276.3%	$256K+462.9%	-$27K-72.3%	$138K-32.5%
EBITDA	-$416K-246.1%	$107K-59.7%	-$195K-1091.7%	-$363K-330.5%	$285K+286.1%	$266K+555.3%	-$16K-253.6%	$158K-26.9%
Interest Expense	$3K-29.8%	$776-84.1%	$4K-18.2%	$8K+104.8%	$5K-17.6%	$5K-15.8%	$5K-5.2%	$4K-40.3%
Income Tax	$0	$0	$0	$0	$0	$0	$0	$0
Net Income	$2.4M+774.3%	$98K-60.3%	-$240K-644.5%	-$380K-382.5%	$271K+267.4%	$246K+422.4%	-$32K-52.0%	$134K-32.2%
EPS (Basic)	$0.16+700.0%	$0.01-50.0%	-$0.03-200.0%	-$0.03-250.0%	$0.02+200.0%	$0.02+300.0%	-$0.01	$0.02
EPS (Diluted)	$0.16+700.0%	$0.01-50.0%	-$0.03	-$0.03	$0.02	$0.02	-$0.01	$0.02
Diluted Shares (Avg)	15M+2.4%	14M+2.4%	7M	N/A	14M	14M	7M0.0%	N/A

ESMC Balance Sheet

ESMC quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Total Assets	$5.0M+4.9%	$4.8M-10.4%	$5.3M+2.6%	$5.2M-9.0%	$5.7M-0.7%	$5.7M+11.6%	$5.1M-5.5%	$5.4M+8.9%	$5.0M-9.9%	$5.5M-15.6%	$6.5M-14.5%	$7.7M+5.3%	$7.3M-25.4%	$9.8M-43.6%	$17.3M
Current Assets	$4.6M+4.9%	$4.4M-5.2%	$4.6M+10.8%	$4.2M-8.9%	$4.6M+6.0%	$4.3M+1.7%	$4.3M-7.1%	$4.6M+10.3%	$4.2M-8.5%	$4.5M-21.3%	$5.8M-16.4%	$6.9M+5.7%	$6.5M-17.2%	$7.9M-40.6%	$13.3M
Cash & Equivalents	$546K+161.1%	$209K-76.5%	$890K+49.8%	$594K-64.0%	$1.7M+99.9%	$826K+101.6%	$410K0.0%	$410K-24.7%	$544K+1.1%	$538K-64.5%	$1.5M-24.5%	$2.0M+273.4%	$538K-39.6%	$891K-41.2%	$1.5M
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Inventory	$2.1M+32.8%	$1.6M+1.6%	$1.6M-1.0%	$1.6M+13.2%	$1.4M-20.6%	$1.8M-5.0%	$1.9M+3.0%	$1.8M-4.9%	$1.9M-9.0%	$2.1M-5.1%	$2.2M-23.7%	$2.9M0.0%	$2.9M+102.9%	$1.4M-71.4%	$5.0M
Accounts Receivable	$1.5M-29.2%	$2.1M+28.4%	$1.7M+7.3%	$1.5M+42.5%	$1.1M-17.6%	$1.3M-12.2%	$1.5M+7.9%	$1.4M-6.5%	$1.5M-8.1%	$1.6M-9.6%	$1.8M+5.7%	$1.7M-2.1%	$1.7M+28.4%	$1.3M-64.7%	$3.8M
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$0-100.0%	$125K0.0%	$125K0.0%	$125K0.0%	$125K0.0%	$125K-42.7%	$218K
Total Liabilities	$3.1M+4.4%	$2.9M-12.6%	$3.4M-8.7%	$3.7M-12.5%	$4.2M+0.3%	$4.2M+42.0%	$3.0M-1.6%	$3.0M-20.7%	$3.8M+5.0%	$3.6M+1.7%	$3.6M-15.1%	$4.2M+21.8%	$3.4M-62.2%	$9.1M-17.9%	$11.1M
Current Liabilities	$2.7M+0.6%	$2.7M-6.5%	$2.9M-5.0%	$3.0M-11.6%	$3.4M+18.6%	$2.9M+26.8%	$2.3M+0.6%	$2.2M-25.1%	$3.0M+7.8%	$2.8M+0.8%	$2.8M-17.6%	$3.4M+33.0%	$2.5M-68.8%	$8.1M+44.1%	$5.6M
Non-Current Liabilities	$393K+40.6%	$279K-46.3%	$520K-24.9%	$692K-16.2%	$826K-38.6%	$1.3M+90.9%	$705K-8.1%	$768K-4.0%	$799K-4.3%	$836K+4.8%	$797K-5.3%	$842K-8.9%	$924K-11.4%	$1.0M-81.0%	$5.5M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$0	N/A	N/A	N/A	N/A	$0-100.0%	$4.5M
Total Equity	$1.9M+5.8%	$1.8M-6.5%	$1.9M+30.9%	$1.5M+1.2%	$1.5M-3.4%	$1.5M-30.1%	$2.2M-10.4%	$2.4M+103.8%	$1.2M-38.0%	$1.9M-36.1%	$3.0M-13.7%	$3.5M-9.5%	$3.8M+493.8%	$645K-89.6%	$6.2M
Retained Earnings	-$68.4M+0.2%	-$68.5M-0.2%	-$68.4M+0.7%	-$68.9M0.0%	-$68.9M-0.1%	-$68.8M-1.0%	-$68.2M-0.4%	-$67.9M+0.9%	-$68.5M-1.1%	-$67.8M-1.7%	-$66.6M-0.8%	-$66.1M-0.6%	-$65.7M+3.8%	-$68.3M-9.5%	-$62.4M

Metric	Q3'2610-Q	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K
Total Assets	$7.5M+44.4%	$5.0M+11.0%	$4.6M-2.9%	$5.0M+4.9%	$5.2M+13.4%	$4.5M-4.7%	$4.7M-4.2%	$4.8M-10.4%
Current Assets	$6.6M+35.6%	$4.3M-0.4%	$4.2M-5.1%	$4.6M+4.9%	$4.8M+16.6%	$4.3M+3.2%	$4.4M+2.8%	$4.4M-5.2%
Cash & Equivalents	$3.3M+517.9%	$337K-35.2%	$616K+168.1%	$546K+161.1%	$541K-4.2%	$521K+33.3%	$230K-69.2%	$209K-76.5%
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Inventory	$1.7M-5.0%	$1.5M-11.3%	$1.7M-3.3%	$2.1M+32.8%	$1.7M-3.4%	$1.7M+22.1%	$1.8M+18.9%	$1.6M+1.6%
Accounts Receivable	$1.3M-37.0%	$2.2M+38.9%	$1.3M-30.8%	$1.5M-29.2%	$2.1M+56.6%	$1.6M-15.4%	$1.9M+27.4%	$2.1M+28.4%
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$3.4M+15.9%	$3.2M+30.2%	$2.9M-1.2%	$3.1M+4.4%	$2.9M-0.1%	$2.5M-14.1%	$2.9M-2.4%	$2.9M-12.6%
Current Liabilities	$2.5M+0.6%	$2.6M+17.7%	$2.5M-5.7%	$2.7M+0.6%	$2.5M-4.2%	$2.2M-13.1%	$2.7M+2.9%	$2.7M-6.5%
Non-Current Liabilities	$853K+112.3%	$604K+140.0%	$377K+44.8%	$393K+40.6%	$402K+36.3%	$252K-22.6%	$260K-36.5%	$279K-46.3%
Total Equity	$4.1M+80.7%	$1.8M-12.4%	$1.7M-5.7%	$1.9M+5.8%	$2.3M+37.0%	$2.0M+10.1%	$1.8M-7.1%	$1.8M-6.5%
Retained Earnings	-$66.2M+2.7%	-$68.6M-0.4%	-$68.7M-0.1%	-$68.4M+0.2%	-$68.1M+0.9%	-$68.3M+0.3%	-$68.6M-0.2%	-$68.5M-0.2%

Not reported in any period shown, so not listed: Goodwill, Long-Term Debt.

ESMC Cash Flow Statement

ESMC quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Operating Cash Flow	-$136K	$381K+163.2%	-$603K-285.4%	$325K+131.0%	-$1.0M-225.2%	$839K+597.8%	-$168K+64.4%	-$473K-542.9%	$107K+121.1%	-$506K+57.7%	-$1.2M-162.2%	-$457K+26.7%	-$623K+67.8%	-$1.9M-176.1%	-$701K-36.0%	-$515K
Depreciation & Amortization	N/A	$38K-17.8%	$46K+1.8%	$45K-6.7%	$48K+8.1%	$45K-10.5%	$50K-0.1%	$50K+1.9%	$49K+7.2%	$46K+86.3%	$25K+72.4%	$14K+13.6%	$13K-11.8%	$14K-39.2%	$23K-95.9%	$571K
Stock-Based Compensation	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$0	$0	N/A	N/A	$52K+319.6%	$12K-71.8%	$44K-40.1%	$73K-33.9%	$111K
Capital Expenditures	$8K	$4K-90.4%	$40K+502.4%	$7K	$0-100.0%	$9K-84.3%	$60K+170.2%	$22K-24.6%	$29K	$0-100.0%	$57K+56.2%	$36K+60.9%	$23K+290.0%	$6K-56.0%	$13K-94.8%	$252K
Free Cash Flow	-$144K	$377K+158.6%	-$643K-301.9%	$318K+130.3%	-$1.0M-226.6%	$829K+463.3%	-$228K+53.9%	-$495K-739.4%	$77K+115.3%	-$506K+59.6%	-$1.3M-154.4%	-$493K+23.6%	-$645K+66.7%	-$1.9M-171.8%	-$714K+7.0%	-$767K
Investing Cash Flow	$2.8M	-$4K+90.4%	-$40K-191.0%	-$14K	$0+100.0%	-$9K+84.3%	-$60K-170.2%	-$22K	N/A	N/A	N/A	N/A	-$23K-100.3%	$6.5M+8293.5%	-$79K+80.3%	-$402K
Financing Cash Flow	-$136K	-$40K-6.6%	-$37K-143.7%	-$15K-121.8%	-$7K-89.2%	-$4K-100.6%	$647K+1819.7%	$34K+124.5%	$15K	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$19K	$0	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q3'2610-Q	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K
Operating Cash Flow	$281K+815.4%	-$517K-271.9%	$85K+155.1%	$16K+104.6%	$31K-82.5%	$301K+193.4%	$33K+128.7%	-$340K-195.8%
Depreciation & Amortization	$3K-65.9%	$8K-14.6%	$8K-23.1%	$9K-55.6%	$9K+145.3%	$10K-18.9%	$11K-3.6%	$19K+78.6%
Capital Expenditures	$0	$0	$4K	$4K-58.0%	$0-100.0%	$0-100.0%	$0-100.0%	$9K
Free Cash Flow	$281K+815.4%	-$517K-271.9%	$81K+141.8%	$12K+103.4%	$31K-81.5%	$301K+187.5%	$33K+124.8%	-$349K-198.4%
Investing Cash Flow	$2.8M	$0	-$4K	-$4K+58.0%	$0-100.0%	$0+100.0%	$0+100.0%	-$9K
Financing Cash Flow	-$101K-875.7%	-$18K-74.9%	-$11K+16.1%	-$7K-6.1%	-$10K-2.0%	-$10K+2.4%	-$13K-20.1%	-$7K+31.5%

Not reported in any period shown, so not listed: Stock-Based Compensation, Dividends Paid, Share Buybacks.

ESMC Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

ESMC quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Gross Margin	45.8%+2.8pp	43.0%-2.1pp	45.0%+2.0pp	43.0%+0.8pp	42.3%-2.4pp	44.7%-3.4pp	48.1%+3.3pp	44.8%-1.1pp	45.9%-0.6pp	46.5%-0.2pp	46.7%+62.7pp	-16.1%-64.7pp	48.6%-1.1pp	49.8%+17.2pp	32.6%
Operating Margin	1.1%+2.0pp	-0.9%-4.8pp	3.9%+8.3pp	-4.4%-4.1pp	-0.3%+14.6pp	-14.9%-12.3pp	-2.6%-4.4pp	1.8%+7.4pp	-5.6%+4.3pp	-9.8%-1.8pp	-8.0%-1.4pp	-6.6%+4.1pp	-10.7%+0.8pp	-11.5%+7.5pp	-19.0%
Net Margin	0.9%+1.9pp	-1.1%-4.8pp	3.8%+3.6pp	0.2%+0.7pp	-0.5%+6.4pp	-6.9%-4.3pp	-2.6%-7.7pp	5.1%+11.6pp	-6.5%+3.5pp	-10.0%-5.8pp	-4.1%+2.9pp	-7.0%-29.9pp	22.8%+74.7pp	-51.9%-29.4pp	-22.5%
Return on Equity	5.5%+12.4pp	-6.9%-30.5pp	23.6%+22.4pp	1.2%+4.8pp	-3.6%+39.4pp	-43.0%-31.4pp	-11.6%-35.8pp	24.2%+85.6pp	-61.4%-1.1pp	-60.3%-42.2pp	-18.1%-7.1pp	-11.0%-79.6pp	68.5%+990.4pp	-921.9%-828.9pp	-93.0%
Return on Assets	2.1%+4.7pp	-2.6%-11.2pp	8.6%+8.3pp	0.4%+1.3pp	-0.9%+10.4pp	-11.4%-6.5pp	-4.9%-15.6pp	10.8%+25.3pp	-14.6%+6.2pp	-20.8%-12.6pp	-8.3%-3.3pp	-5.0%-41.1pp	36.1%+97.1pp	-61.0%-27.6pp	-33.3%
Current Ratio	1.72+0.1x	1.650.0x	1.63+0.2x	1.390.0x	1.35-0.2x	1.51-0.4x	1.89-0.2x	2.04+0.7x	1.38-0.2x	1.63-0.5x	2.090.0x	2.06-0.5x	2.59+1.6x	0.98-1.4x	2.37
Debt-to-Equity	1.610.0x	1.63-0.1x	1.74-0.8x	2.50-0.4x	2.89+0.1x	2.78+1.4x	1.37+0.1x	1.25+1.2x	0.00-1.9x	1.89+0.7x	1.190.0x	1.21+0.3x	0.90+0.9x	0.00-0.7x	0.73
Asset Turnover	2.41-0.1x	2.52+0.2x	2.29+0.2x	2.07+0.2x	1.84+0.2x	1.64-0.2x	1.88-0.2x	2.10-0.2x	2.25+0.2x	2.09+0.1x	2.01+1.3x	0.71-0.9x	1.58+0.4x	1.18-0.3x	1.48
FCF Margin	3.1%+8.5pp	-5.4%-8.0pp	2.6%+12.4pp	-9.8%-17.7pp	7.9%+10.4pp	-2.4%+2.7pp	-5.1%-5.8pp	0.7%+5.2pp	-4.5%+6.3pp	-10.8%-7.1pp	-3.8%+8.1pp	-11.9%+5.0pp	-16.9%-10.6pp	-6.2%-3.2pp	-3.0%

Metric	Q3'2610-Q	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K
Gross Margin	36.3%-9.8pp	43.3%-5.5pp	41.9%-1.7pp	43.7%+1.4pp	46.1%+4.6pp	48.9%+4.9pp	43.6%-0.4pp	42.4%-4.1pp
Operating Margin	-16.1%-24.0pp	2.8%-5.2pp	-7.6%-6.6pp	-14.5%-18.4pp	8.0%+13.8pp	8.0%+10.4pp	-1.0%-0.4pp	4.0%-2.5pp
Net Margin	91.0%+83.2pp	2.7%-4.9pp	-9.0%-7.8pp	-14.8%-18.6pp	7.8%+13.8pp	7.6%+10.3pp	-1.2%-0.4pp	3.9%-2.5pp
Return on Equity	57.2%+45.4pp	5.5%-6.7pp	-14.3%-12.5pp	-19.8%-27.3pp	11.8%+21.5pp	12.2%+16.3pp	-1.8%-0.7pp	7.4%-2.8pp
Return on Assets	31.5%+26.3pp	2.0%-3.5pp	-5.2%-4.6pp	-7.6%-10.4pp	5.2%+8.7pp	5.5%+7.1pp	-0.7%-0.2pp	2.8%-0.9pp
Current Ratio	2.59+0.7x	1.65-0.3x	1.670.0x	1.72+0.1x	1.92+0.3x	1.95+0.3x	1.660.0x	1.650.0x
Debt-to-Equity	0.82-0.5x	1.81+0.6x	1.73+0.1x	1.610.0x	1.27-0.5x	1.22-0.3x	1.66+0.1x	1.63-0.1x
Asset Turnover	0.35-0.3x	0.720.0x	0.580.0x	0.51-0.2x	0.67+0.1x	0.72+0.1x	0.590.0x	0.73+0.1x
FCF Margin	10.8%+9.9pp	-14.4%-23.8pp	3.0%+1.8pp	0.5%+10.5pp	0.9%-5.3pp	9.3%+21.3pp	1.2%+5.8pp	-10.1%-21.4pp

Where ESCALON MEDICAL CORP Ranks

Frequently Asked Questions

What is ESCALON MEDICAL CORP's annual revenue?

ESCALON MEDICAL CORP (ESMC) reported $12.0M in total revenue for fiscal year 2025. This represents a 0.5% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is ESCALON MEDICAL CORP's revenue growing?

ESCALON MEDICAL CORP (ESMC) revenue grew by 0.5% year-over-year, from $12.0M to $12.0M in fiscal year 2025.

Is ESCALON MEDICAL CORP profitable?

Yes, ESCALON MEDICAL CORP (ESMC) reported a net income of $106K in fiscal year 2025, with a net profit margin of 0.9%.

What is ESCALON MEDICAL CORP's EBITDA?

ESCALON MEDICAL CORP (ESMC) had EBITDA of $171K in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is ESCALON MEDICAL CORP's gross margin?

ESCALON MEDICAL CORP (ESMC) had a gross margin of 45.8% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is ESCALON MEDICAL CORP's operating margin?

ESCALON MEDICAL CORP (ESMC) had an operating margin of 1.1% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is ESCALON MEDICAL CORP's net profit margin?

ESCALON MEDICAL CORP (ESMC) had a net profit margin of 0.9% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is ESCALON MEDICAL CORP's return on equity (ROE)?

ESCALON MEDICAL CORP (ESMC) has a return on equity of 5.5% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is ESCALON MEDICAL CORP's free cash flow?

ESCALON MEDICAL CORP (ESMC) generated $377K in free cash flow during fiscal year 2025. This represents a 158.6% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is ESCALON MEDICAL CORP's operating cash flow?

ESCALON MEDICAL CORP (ESMC) generated $381K in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are ESCALON MEDICAL CORP's total assets?

ESCALON MEDICAL CORP (ESMC) had $5.0M in total assets as of fiscal year 2025, including both current and long-term assets.

What are ESCALON MEDICAL CORP's capital expenditures?

ESCALON MEDICAL CORP (ESMC) invested $4K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does ESCALON MEDICAL CORP spend on research and development?

ESCALON MEDICAL CORP (ESMC) invested $753K in research and development during fiscal year 2025.

How many shares does ESCALON MEDICAL CORP have outstanding?

ESCALON MEDICAL CORP (ESMC) had 7M shares outstanding as of fiscal year 2025.

What is ESCALON MEDICAL CORP's current ratio?

ESCALON MEDICAL CORP (ESMC) had a current ratio of 1.72 as of fiscal year 2025, which is generally considered healthy.

What is ESCALON MEDICAL CORP's debt-to-equity ratio?

ESCALON MEDICAL CORP (ESMC) had a debt-to-equity ratio of 1.61 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is ESCALON MEDICAL CORP's return on assets (ROA)?

ESCALON MEDICAL CORP (ESMC) had a return on assets of 2.1% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is ESCALON MEDICAL CORP's P/E ratio?

ESCALON MEDICAL CORP (ESMC) trades at 0.6x earnings, its market capitalization divided by net income of $1.9M net income, trailing 12 months to March 31, 2026. The market capitalization is $1.2M as of Sep 14, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is ESCALON MEDICAL CORP's price-to-sales ratio?

ESCALON MEDICAL CORP (ESMC) trades at 0.1x sales, its market capitalization divided by revenue of $11.4M revenue, trailing 12 months to March 31, 2026. The market capitalization is $1.2M as of Sep 14, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is ESCALON MEDICAL CORP's Altman Z-Score?

ESCALON MEDICAL CORP (ESMC) has an Altman Z-Score of -16.00, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is ESCALON MEDICAL CORP's Piotroski F-Score?

ESCALON MEDICAL CORP (ESMC) has a Piotroski F-Score of 7 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are ESCALON MEDICAL CORP's earnings high quality?

ESCALON MEDICAL CORP (ESMC) has an earnings quality ratio of 3.61x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can ESCALON MEDICAL CORP cover its interest payments?

ESCALON MEDICAL CORP (ESMC) has an interest coverage ratio of 5.87x, meaning it can comfortably cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.